Literature DB >> 18060435

Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression.

Eirini Nestoridi1, Rafail I Kushak, Olga Tsukurov, Eric F Grabowski, Julie R Ingelfinger.   

Abstract

Current evidence implicates a prothrombotic state in the development of Shiga-toxin (Stx)-mediated hemolytic uremic syndrome (HUS). We recently reported that Stx modulates procoagulant activity by enhancing functional tissue factor (TF) activity on cytokine-activated human glomerular endothelial cells (HGECs). Since angiotensin II (Ang II), the key effector of the renin angiotensin system (RAS), has been shown to increase TF expression in vascular tissue, we examined the possible involvement of Ang II in TF expression in HGECs. HGECs were exposed to tumor necrosis factor (TNF)-alpha +/- Stx-1 +/- Ang II. Exogenous Ang II significantly increased TF activity and TF mRNA in TNF-alpha- +/- Stx-1-activated HGECs. This increase was mediated via Ang II type I receptor (AT(1)R), as losartan, an AT(1)R inhibitor, attenuated Ang-II-induced TF activity. To study the effect of endogenous Ang II in TF expression by TNF-alpha +/- Stx-1, HGECs were incubated with losartan or an AT(2)R inhibitor (PD 123319) or an angiotensin-converting enzyme inhibitor (enalapril). Losartan but not PD 123319 decreased TF activity induced by TNF-alpha +/- Stx-1 (P < 0.05). Enalapril, also, dose dependently, downregulated TF expression in HGECs exposed to TNF-alpha +/- Stx-1 (P < 0.05). AT(1)R mRNA was upregulated in TNF-alpha- +/- Stx-1-activated HGECs (P < 0.05). These data indicate that TF expression in TNF-alpha- and Stx-1-activated HGECs is enhanced by exogenous Ang II and that endogenous Ang II production may be upregulated by TNF-alpha +/- Stx-1. Hence, local RAS activation may be important in the development of the thrombotic microangiopathy observed in HUS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18060435      PMCID: PMC5994138          DOI: 10.1007/s00467-007-0636-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  33 in total

1.  Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy.

Authors:  Sharon P Andreoli; Howard Trachtman; David W K Acheson; Richard L Siegler; Tom G Obrig
Journal:  Pediatr Nephrol       Date:  2002-04       Impact factor: 3.714

2.  Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data.

Authors:  Christian Ramakers; Jan M Ruijter; Ronald H Lekanne Deprez; Antoon F M Moorman
Journal:  Neurosci Lett       Date:  2003-03-13       Impact factor: 3.046

3.  Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome.

Authors:  C H Nevard; A D Blann; K M Jurd; G B Haycock; B J Hunt
Journal:  Pediatr Nephrol       Date:  1999-08       Impact factor: 3.714

Review 4.  Physiology of local renin-angiotensin systems.

Authors:  Martin Paul; Ali Poyan Mehr; Reinhold Kreutz
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

Review 5.  Cell biology of tissue factor, the principal initiator of blood coagulation.

Authors:  E Camerer; A B Kolstø; H Prydz
Journal:  Thromb Res       Date:  1996-01-01       Impact factor: 3.944

Review 6.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

7.  Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney.

Authors:  A Tufro-McReddie; R A Gomez; L L Norling; A A Omar; L C Moore; F J Kaskel
Journal:  Kidney Int       Date:  1993-03       Impact factor: 10.612

Review 8.  The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking.

Authors:  D M Monroe; N S Key
Journal:  J Thromb Haemost       Date:  2007-06       Impact factor: 5.824

9.  Cultured human endothelial cells generate tissue factor in response to endotoxin.

Authors:  M Colucci; G Balconi; R Lorenzet; A Pietra; D Locati; M B Donati; N Semeraro
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

10.  Systemic hypertension and plasma renin activity in children with the hemolytic-uremic syndrome.

Authors:  B Grunfeld; M Gimenez; S Liapchuc; J Mendilaharzu; C Gianantonio
Journal:  Int J Pediatr Nephrol       Date:  1982-09
View more
  7 in total

1.  Enzymatic processing of angiotensin peptides by human glomerular endothelial cells.

Authors:  Juan Carlos Q Velez; Jessalyn L Ierardi; Alison M Bland; Thomas A Morinelli; John M Arthur; John R Raymond; Michael G Janech
Journal:  Am J Physiol Renal Physiol       Date:  2012-03-28

2.  Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Lisa Sartz; Anders Nelsson; Zivile D Békássy; Diana Karpman
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

3.  Lipopolysaccharide renders transgenic mice expressing human serum amyloid P component sensitive to Shiga toxin 2.

Authors:  Thomas P Griener; Jonathan G Strecker; Romney M Humphries; George L Mulvey; Carmen Fuentealba; Robert E W Hancock; Glen D Armstrong
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

4.  The effect of high glucose on the inhibitory action of C21, a selective AT2R agonist, of LPS-stimulated tissue factor expression in human mononuclear cells.

Authors:  Cristina Balia; Valentina Scalise; Silvana Cianchetti; Francesca Faita; Tommaso Neri; Vittoria Carnicelli; Riccardo Zucchi; Alessandro Celi; Roberto Pedrinelli
Journal:  J Inflamm (Lond)       Date:  2016-05-04       Impact factor: 4.981

5.  Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome.

Authors:  V Raghunathan; S K Sethi; M A Dragon-Durey; M Dhaliwal; R Raina; P Jha; S B Bansal; V Kher
Journal:  Indian J Nephrol       Date:  2017 Mar-Apr

Review 6.  The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19.

Authors:  M Ekholm; T Kahan
Journal:  Front Pharmacol       Date:  2021-06-17       Impact factor: 5.810

Review 7.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Johanna Scheiring; Sharon P Andreoli; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.